PharmaLex announces merger with Ascent to extend reach in Asia
Category: #health  By Pankaj Singh  Date: 2022-02-11
 | 
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

PharmaLex announces merger with Ascent to extend reach in Asia

PharmaLex Group, a service provider for medtech, biotech, and pharma industries globally, has reportedly merged with Tokyo-based biopharma services provider Ascent Development Services.

The merger provides access to an impressive client portfolio and enhances the global footprint of the PharmaLex Group not only in Japan but also in other markets across Southeast and East Asia. Ascent will be able to use full-service abilities, both globally and locally, for upcoming biopharma firms to fully adopt globally integrated development of pharmaceutical products including Asia.

Talking about the merger, John Winebarger, the Chief Executive Officer of Ascent expressed that the move offers its current and upcoming clients access to a strong set of integrated and comprehensive product development capabilities across the EU, Asia, and the U.S.

Winebarger added that the company’s highly aligned strategy and strong cultural fit will continue to offer its distinct Asia-oriented services whilst using the complementary services of PharmaLex in the EU and the U.S.  in order to offer support of entirely global planning and implementation of drug development.

Dr. Thomas Dobmeyer, the Chief Executive Officer of PharmaLex believes that the merger allows the company to continue its aim of offering support for integrated product development to customers across the world, and to serve upcoming biopharma firms by consolidating Southeast and East Asia into global programs of clinical development.

Dr. Dobmeyer has welcomed the opportunity of upscaling the company’s depth to its developing services of consultation and scientific affairs.

Notably, Ascent works with upcoming biopharma companies to understand and vanquish challenges in culture, practice, and language. The company intends to assist the operational and strategic integration of Asia into drug development across the world.

Founded in 2017 and based in Tokyo, the firm employs staff throughout Asia including Korea, China, the Philippines, Malaysia, Taiwan, Singapore, Vietnam, and Thailand.

Source credit:

https://www.cleanroomtechnology.com/news/article_page/Pharma_services_expert_PharmaLex_extends_reach_in_Asia_with_merger/198697



About Author

Pankaj Singh

Email: [email protected]   linkdin twitter

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

More News By Pankaj Singh

Rona Therapeutics obtains global rights to Sanofi's siRNA platform

Rona Therapeutics obtains global rights to Sanofi's siRNA platform

By Pankaj Singh

Rona Therapeutics Inc has reportedly acquired the global exclusive rights to the siRNA platform of delivery moiety and chemical modification from Sanofi S.A., in addition to four pre-clinical contenders for unrevealed ...

Toy maker Mattel inks multi-year agreement with Elon Musk’s SpaceX

Toy maker Mattel inks multi-year agreement with Elon Musk’s SpaceX

By Pankaj Singh

California-based toy manufacturing and entertainment company, Mattel, has recently signed a multi-year agreement with Elon Musk’s private spaceflight company, SpaceX.

T...

USHV partners with Willowbrook to provide quality cardiovascular care

USHV partners with Willowbrook to provide quality cardiovascular care

By Pankaj Singh

US Heart & Vascular (USHV) is reportedly partnering with Willowbrook Cardiovascular Associates to offer quality cardiovascular care in the Houston market.

USHV has a strong ma...